Press Releases
 2008
PRESS RELEASE: 24 April 2008
BIOSIMILAR MEDICINES – DEVELOPING
MARKET PATHWAYS
THAT BENEFIT PATIENTS IS A SHARED RESPONSIBILITY
EGA Director General Greg Perry congratulated industry and EU medicines regulatory authorities today for further consolidating and developing the EU’s rigorously scientific “biosimilar thinking” during 2007.
PRESS RELEASE: 20 March 2008
THE EGA WELCOMES COMMISSION PROPOSAL AGAINST COUNTERFEITING OF MEDICINES — KEY ACTIONS AND INITIATIVES HIGHLIGHTED
The EGA considers the key proposals to be well designed to target the genuine problems underlying the counterfeiting of medicines.
PRESS RELEASE: 31 January 2008
EGA REITERATES LACK OF RESOURCES FOR NATIONAL REGULATORY AUTHORITIES AS MAJOR BARRIER TO NEW GENERIC MEDICINES
The EGA has reiterated its plea to the National Medicines Authorities to resolve their issues of resources to ensure the rapid and efficient approval of new generic medicines.
PRESS RELEASE: 16 January 2008
EUROPEAN COMMISSION INQUIRY
INTO COMPETITION IN THE PHARMACEUTICAL SECTOR
2007
EGA NEWS: 29 November 2007
Japanese Genereric Pharmaceutical Manufacturers Association Joins IGPA
Mr Hiroyuki Sawai accepts membership during the 10th Annual IGPA Conference in Miami.
PRESS RELEASE: 21 November 2007
PUBLIC INFORMATION LAUNCHED ON BIOSIMILAR MEDICINES
The European Generic medicines Association (EGA) launched its handbook
on biosimilar medicines today in Brussels.
PRESS RELEASE: 21 November 2007
EGA ELECTS ERIC GORKA AS PRESIDENT: FOCUS WILL BE ON SPEEDING NEW MEDICINES TO MARKET
The European Generic medicines Association (EGA) has elected Eric Gorka, Head Commercial Operations EMEA for Sandoz International, as its new president.
PRESS RELEASE: 20 September 2007
EUROPEAN GENERIC MEDICINES INDUSTRY LAUNCHES PACT AGAINST THE COUNTERFEITING OF MEDICINES
The European Generic medicines Association (EGA) has today launched a plan to establish a supply chain integrity pact to fight the counterfeiting of pharmaceuticals.
PRESS RELEASE: 3 September 2007
EGA WELCOMES APPROVAL OF FIRST BIOSIMILAR EPOETIN
The new biosimilar medicines, based on one development, have been shown to match a previously approved reference product in terms of quality, safety and efficacy...
PRESS RELEASE: 26 June 2007
EGA URGES PRICE DELINKAGE FOR OFF-PATENT MEDICINES AT EU HIGH LEVEL FORUM ON PHARMACEUTICALS
Speaking today at the High Level Forum on Pharmaceuticals, EGA President Emile Loof urged European medicines regulators not to link the price of generic medicines to the price of their corresponding originator products.
PRESS RELEASE: 24 May 2007
3rd EGA SOUTH EAST EUROPE SYMPOSIUM:
“Meeting the European Challenge for the National Drug Regulatory Agencies and the Generic Medicines Industry”
Greg Perry praised representatives
from thirteen regional medicines agencies for their commitment to understanding
EU legislation, and cautioned against adopting provisions which could
negativly impact the availability of affordable generic medicines in
the region.
PRESS RELEASE: 14 May 2007
KEEPING COUNTERFEIT MEDICINES OUT OF THE EU:
A PROPORTIONAL AND TARGETED APPROACH REQUIRED
Greg Perry, EGA Director General, presents the generic
medicines industry's position on anti-counterfeiting policy at the
European Parliament, expressing strong support for Europe’s record
of protecting pharmaceutical supplies from counterfeiters.
PRESS RELEASE: 3 May 2007
BUILDING A “MARKET PATHWAY” FOR BIOSIMILAR MEDICINES
Now that the science and the regulatory pathway have been established in the EU, industry and regulators must focus on building a “market pathway” for biosimilar medicines.
PRESS RELEASE: 13 February 2007
LACK OF AGENCY RESOURCES DELAYING GENERIC MEDICINES APPLICATIONS
While praising EU regulators for the smooth implementation and running of the new Decentralised Procedure (DCP), the EGA is concerned about the serious lack of resources available to Member State agencies to deal with the regulatory workload.
|
